文献速递精神分裂症与精神病性障碍

氯氮平联合特定剂量其他抗精神病药治疗精神分裂症的有效性:两项全国队列的荟萃分析

Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts.
PubMed 文献 · World Psychiatry · 2025-01-01

荟萃分析显示,仅中剂量阿立哌唑(9至<16.5 mg/日)联合高剂量氯氮平(≥330 mg/日)与精神病性发作住院风险显著降低相关(aHR=0.68,95%CI 0.62-0.75),而所有高剂量联合均与住院风险增加相关。

要点

  • 中剂量阿立哌唑联合高剂量氯氮平与精神病性发作住院风险降低相关。
  • 所有高剂量抗精神病药联合氯氮平均与精神病性住院风险增加相关。
  • 仅阿立哌唑联合与精神病性或躯体原因住院风险降低相关。

核心结论

  • 中剂量阿立哌唑联合氯氮平治疗与严重复发风险降低20-30%相关,而高剂量阿立哌唑及其他抗精神病药高剂量联合与复发风险增加相关。

研究设计与样本

  • 基于芬兰(1995-2017年,N=14,053)和瑞典(2006-2021年,N=8,743)全国登记数据的群体研究,采用个体内设计以消除选择偏倚,使用分层Cox模型分析,并采用随机效应荟萃分析合并两国结果。

主要发现

  • 中剂量阿立哌唑(9至<16.5 mg/日)联合高剂量氯氮平(≥330 mg/日)在两国均与精神病性发作住院风险显著降低相关,荟萃分析aHR=0.68(95%CI 0.62-0.75,p<0.0001)。
  • 在中剂量氯氮平(180至<330 mg/日)患者中,中剂量阿立哌唑联合是唯一经Bonferroni校正后优于氯氮平单药的治疗(aHR=0.79,95%CI 0.70-0.91,p=0.0006)。
  • 所有高剂量联合均与精神病性发作住院风险增加相关。
  • 仅阿立哌唑联合与精神病性或躯体原因住院风险降低相关,中剂量阿立哌唑联合高剂量氯氮平风险最低(aHR=0.70,95%CI 0.58-0.84,p=0.0001)。

关键数值与推荐

  • 中剂量阿立哌唑定义为9至<16.5 mg/日,高剂量氯氮平定义为≥330 mg/日,中剂量氯氮平定义为180至<330 mg/日。
  • 主要结局为精神病性发作住院风险,次要结局为躯体住院及精神病性或躯体原因住院。

临床怎么用

  • 对于氯氮平治疗反应不佳的精神分裂症或分裂情感障碍患者,可考虑中剂量阿立哌唑联合高剂量氯氮平以降低严重复发风险。
  • 应避免高剂量阿立哌唑及其他抗精神病药高剂量联合氯氮平,因与复发风险增加相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although clozapine is the most effective medication for treatment-resistant schizophrenia, response is inadequate in over half of people with that condition. There is limited guidance available on effective clozapine augmentation strategies. We studied the comparative effectiveness of specific doses of oral olanzapine, quetiapine, risperidone and aripiprazole augmentation of clozapine treatment on the risk of hospitalization due to a psychotic episode, as a marker for severe relapse, among patients with schizophrenia or schizoaffective disorder. In this population-based study, patients with one of those diagnoses receiving clozapine were identified from Finnish (years 1995-2017, N=14,053) and Swedish (years 2006-2021, N=8,743) nationwide registers. The risk of hospitalization due to a psychotic episode associated with periods of antipsychotic augmentation of clozapine treatment vs. same-dose clozapine monotherapy was assessed by a within-individual design, using each individual as his/her own control to eliminate selection bias, and analyzed with stratified Cox models. The two national cohorts were first analyzed separately; then results were combined using a random-effect meta-analysis. Secondary outcomes were somatic hospitalization, and hospitalization for psychosis or a somatic cause. The only augmentation associated with a significantly decreased risk of hospitalization due to psychosis in both countries was medium-dose (9 to <16.5 mg/day) aripiprazole combined with high-dose (≥330 mg/day) clozapine, and this combination was associated with the best outcome in the meta-analysis (adjusted hazard ratio, aHR=0.68, 95% CI: 0.62-0.75, p<0.0001). Among patients using medium-dose (180 to <330 mg/day) clozapine, medium-dose aripiprazole augmentation was the only treatment more effective than clozapine monotherapy after Bonferroni correction (aHR=0.79, 95% CI: 0.70-0.91, p=0.0006). The use of all high-dose augmentations was associated with an increased risk of hospitalization due to psychosis. Only aripiprazole augmentations were associated with a decreased risk of hospitalization for psychosis or a somatic cause, and the lowest risk was observed for medium-dose aripiprazole plus high-dose clozapine (aHR=0.70, 95% CI: 0.58-0.84, p=0.0001). This meta-analysis of two nationwide cohorts, totaling almost 23,000 patients using clozapine, indicates that medium-dose aripiprazole augmentation of clozapine treatment is associated with a 20-30% decreased risk of severe relapse compared with clozapine monotherapy within the same individuals, while augmentation with higher doses of aripiprazole (as well as with high doses of all other antipsychotics) is associated with an increased relapse risk.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tiihonen J, Tanskanen A, Mittendorfer-Rutz E, et al. Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts. World Psychiatry. 2025. PMID: 40371869. doi:10.1002/wps.21316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。